The group aims to determine the feasibility of TROLL-2 and TROLL-3 as diagnostic biomarkers for the prediction of treatment efficacy and prognosis in breast cancer.
The Tampa Bay Times reports that an investigation into foreign ties is being launched following the departure of the CEO, a vice president, and four researchers from the Moffitt Cancer Center.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.
While some groups have communicated their concerns directly to the agency, stakeholders have also formed a new coalition to publicly take issue with FDA's actions.
Pharmacogenetics and legal experts took particular issue with the agency's suggestion that "established" drug/gene relationships are found only in FDA-approved drug labels.
Publishing house Hearst is pushing into precision medicine with a $75 million investment in M2Gen, the informatics subsidiary of Moffitt Cancer Center.
